

Neoadjuvant	Post-Neoadjuvant	Adjuvant	Metastatic
<div><div><div>S2212 (SCARLET) TNBC T2-4/N0/M0, or T1-3/N1-2/M0</div><div>S2206 HR+/HER2- Stage II or III</div></div></div>	<div><div><div>A012103 (OptimICE-PCR) TNBC Early-Stage, pCR post pre-op chemo + pembrolizumab</div><div>A012303 (ShortStop-HER2) HER2+ Early-Stage, pCR post pre-op chemo + HER2 blockade</div></div></div>	<div><div><div>CCTG MA.39 HR+/HER2- Low risk; Node positive</div><div>NRG-BR007 (DEBRA) HR+/HER2- pT1(&lt;=2cm) pN0M0</div><div>NRG-BR009 (OFFSET) HR+/HER2- pT1-3/N0-1/M0, Oncotype Recurrence Score ≤ 25, Premenopausal patients</div><div>A012301 (LoTam) HR+/HER2- Early-stage, Low molecular risk, Resected tumor ≤3cm and N0, Postmenopausal pts</div></div></div>	<div><div><div>EAY191 (ComboMATCH)</div><div>↓</div><div>Sub-study: EAY191-E5 (KRAS G12C mutation)</div></div></div>

## NCTN Breast Cancer Trials (Open as of 1/15/2026)

Protocol Number	Phase	Protocol Title
<b>A012103</b>	III	OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
<b>A012301</b>	III	LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
<b>A012303</b>	III	ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
<b>CCTG MA.39</b>	III	Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
<b>NRG-BR007</b>	III	A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score $\leq 18$ Breast Cancer (DEBRA)
<b>NRG-BR009</b>	III	A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score $\leq 25$ (OFSET)
<b>S2206</b>	III	Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
<b>S2212</b>	III	Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
<b>EAY191</b>	Other	Molecular Analysis for Combination Therapy Choice (ComboMATCH)
<b>EAY191-E5</b>	II	A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial

This portfolio shows NCTN trials. For information about NCORP trials, please see: <https://ncorp.cancer.gov/find-a-study/>